Unveiling therapeutic avenues targeting xCT in head and neck cancer

被引：0
|
作者：
Lee, Jaewang [1 ]
Roh, Jong-Lyel [1 ,2 ]
机构：
[1] CHA Univ, CHA Bundang Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Seongnam 13496, Gyeonggi Do, South Korea
[2] CHA Univ, Gen Grad Sch, Dept Biomed Sci, Pochon, South Korea
来源：
CELLULAR ONCOLOGY | 2024年 / 47卷 / 06期
基金：
新加坡国家研究基金会;
关键词：
xCT; Ferroptosis; Head and neck cancer; Resistance; Therapy; REGULATES FERROPTOSIS; CISPLATIN RESISTANCE; TUMOR PROGRESSION; CIRCULAR RNAS; CELL-DEATH; METABOLISM; PATHWAY; NRF2; TRANSPORTER; EXPRESSION;
D O I：
10.1007/s13402-024-00997-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Head and neck cancer (HNC) remains a major global health burden, prompting the need for innovative therapeutic strategies. This review examines the role of the cystine/glutamate antiporter (xCT) in HNC, specifically focusing on how xCT contributes to cancer progression through mechanisms such as redox imbalance, ferroptosis, and treatment resistance. The central questions addressed include how xCT dysregulation affects tumor biology and the potential for targeting xCT to enhance treatment outcomes. We explore recent developments in xCT-targeted current and emerging therapies, including xCT inhibitors and novel treatment modalities, and their role in addressing therapeutic challenges. This review aims to provide a comprehensive analysis of xCT as a therapeutic target and to outline future directions for research and clinical application.
引用
收藏
页码：2019 / 2030
页数：12
相关论文
共 50 条
  • [31] Targeting head and neck cancer epigenetics with CRISPR-dCas9: An emerging therapeutic approach
    Elumalai, Perumal
    Ezhilarasan, Devaraj
    Lakshmi, Thangavelu
    ORAL ONCOLOGY, 2022, 127
  • [32] The changing therapeutic landscape of head and neck cancer
    Cramer, John D.
    Burtness, Barbara
    Quynh Thu Le
    Ferris, Robert L.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (11) : 669 - 683
  • [33] Targeting EGFR in head and neck cancer: a decade of progress
    Chris Boshoff
    Marshall Posner
    Nature Reviews Clinical Oncology, 2009, 6 : 123 - 123
  • [34] Targeting uroporphyrinogen decarboxylase for head and neck cancer treatment
    Emma Ito
    Shijun Yue
    Eduardo H Moriyama
    Angela B Hui
    Inki Kim
    Wei Shi
    Nehad M Alajez
    Nirmal Bhogal
    GuoHua Li
    Alessandro Datti
    Aaron D Schimmer
    Brian C Wilson
    Peter P Liu
    Daniel Durocher
    Benjamin G Neel
    Brian O’Sullivan
    Bernard Cummings
    Rob Bristow
    Jeff Wrana
    Fei-Fei Liu
    BMC Proceedings, 7 (Suppl 2)
  • [35] Targeting EGFR resistance networks in head and neck cancer
    Ratushny, Vladimir
    Astsaturov, Igor
    Burtness, Barbara A.
    Golemis, Erica A.
    Silverman, Joshua S.
    CELLULAR SIGNALLING, 2009, 21 (08) : 1255 - 1268
  • [36] Targeting EGFR in head and neck cancer: a decade of progress
    Boshoff, Chris
    Posner, Marshall
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (03): : 123 - 123
  • [37] Risk targeting and strategy for chemoprevention of head and neck cancer
    Sudbo, J
    Sondresen, JE
    Reith, A
    Bryne, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S84 - S84
  • [38] Molecular targeting of cetuximab resistant head and neck cancer
    Swick, Adam D.
    Gunderson, Dana
    Smith, Molly
    Blitzer, Grace
    Stein, Andrew
    Nickel, Kwangok P.
    Kimple, Randall J.
    CANCER RESEARCH, 2015, 75
  • [39] Targeting mTOR in Head and Neck Cancer-Letter
    Masterson, Liam
    Lechner, Matt
    Jones, Terry M.
    CLINICAL CANCER RESEARCH, 2019, 25 (21) : 6554 - 6554
  • [40] Therapeutically targeting the cell cycle in head and neck cancer
    Diab, Ahmed
    Chang, Xu
    Kao, Michael
    Clurman, Bruce
    Galloway, Denise
    Eduardo, Mendez
    CLINICAL CANCER RESEARCH, 2017, 23 (23)
12345